Loading...
OTCMMSCLF
Market cap69mUSD
Jan 08, Last price  
0.61USD
1D
2.19%
1Q
28.55%
Jan 2017
-3.89%
IPO
-82.38%
Name

Satellos Bioscience Inc

Chart & Performance

D1W1MN
OTCM:MSCLF chart
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
82.89%
Rev. gr., 5y
%
Revenues
0k
000025,0000000
Net income
-16m
L+40.33%
-1,794,921-1,489,923-1,237,308-1,702,623-1,938,235-1,578,530-15,505,652-11,322,437-15,889,000
CFO
-15m
L+153.81%
-3,095,380-1,332,713-1,220,941-1,104,497-2,237,605-1,659,982-5,033,711-5,713,347-14,501,000

Profile

Satellos Bioscience Inc., a regenerative medicine company, develops therapeutics to treat degenerative muscle diseases. Its lead program focuses on the development of oral therapeutic drug to correct muscle stem cell polarity and restore the body's innate muscle repair and regeneration process. The company was incorporated in 2012 and is headquartered in Toronto, Canada.
URL
https://satellos.com/
IPO date
Dec 01, 2006
Employees
Domiciled in
CA
Incorporated in
CA

Valuation

Title
CAD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
24,280
8,362
Unusual Expense (Income)
NOPBT
(24,280)
(8,362)
NOPBT Margin
Operating Taxes
6
Tax Rate
NOPAT
(24,280)
(8,368)
Net income
(15,889)
40.33%
(11,322)
-26.98%
Dividends
Dividend yield
Proceeds from repurchase of equity
32,463
1,996
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
(39,628)
(1,965)
Cash flow
Cash from operating activities
(14,501)
(5,713)
CAPEX
(18)
(3)
Cash from investing activities
(17,538)
(3)
Cash from financing activities
51,033
2,775
FCF
(24,889)
(7,770)
Balance
Cash
39,587
1,924
Long term investments
41
42
Excess cash
39,628
1,965
Stockholders' equity
14,399
(1,412)
Invested Capital
26,275
4,780
ROIC
ROCE
EV
Common stock shares outstanding
86,405
35,680
Price
Market cap
EV
EBITDA
(24,273)
(8,025)
EV/EBITDA
Interest
Interest/NOPBT